Novo Nordisk A/S : Victoza(R) label in the US updated to include data showing superior efficacy when compared to Januvia(R)
Label update also includes FDA approval of combination therapy with basal insulin for the treatment of adults with type 2 diabetes

BAGSVAERD, DENMARK -- (Marketwire) -- 04/06/12 -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved to update the product label for Victoza® (liraglutide [rDNA] injection) to include data showing superior blood sugar control and weight reduction when compared to Januvia® (sitagliptin).

Company announcement 22 2012: http://hugin.info/2013/R/1600926/505405.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE

[HUG#1600926]

Further information:

Media:

Mike Rulis
Tel: (+45) 3079 3573
Email Contact

Investors:

Klaus Bulow Davidsen
Tel: (+45) 4442 3176
Email Contact

Frank Daniel Mersebach
Tel: (+45) 4442 0604
Email Contact

Lars Borup Jacobsen
Tel: (+45) 3075 3479
Email Contact

In North America:
Ambre Morley
Tel: (+1) 609 216-5240
Email Contact

Jannick Lindegaard
Tel: (+1) 609 786 4575
Email Contact

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here